CLINICAL TRIALS PROFILE FOR IDECABTAGENE VICLEUCEL
✉ Email this page to a colleague
All Clinical Trials for idecabtagene vicleucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06045806 ↗ | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After A | Recruiting | Bristol-Myers Squibb | Phase 3 | 2023-10-16 | The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT). |
| NCT06045806 ↗ | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After A | Recruiting | Celgene | Phase 3 | 2023-10-16 | The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT). |
| NCT06138275 ↗ | Elranatamab in R/R Multiple Myeloma | Recruiting | Pfizer | Phase 2 | 2024-03-08 | This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma. |
| NCT06138275 ↗ | Elranatamab in R/R Multiple Myeloma | Recruiting | Massachusetts General Hospital | Phase 2 | 2024-03-08 | This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma. |
| NCT06179888 ↗ | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2024-12-30 | This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for idecabtagene vicleucel
Condition Name
Clinical Trial Locations for idecabtagene vicleucel
Trials by Country
Clinical Trial Progress for idecabtagene vicleucel
Clinical Trial Phase
Clinical Trial Sponsors for idecabtagene vicleucel
Sponsor Name
